Dihexa — Research Reference

Dihexa (research designation PNB-0408; also referred to as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic hexanoic acid-modified dipeptide derivative developed at Washington State University by Joseph Harding and colleagues. It is investigated for its potential role in synaptogenesis and cognitive enhancement via the hepatocyte growth factor (HGF) / MET receptor tyrosine kinase signalling pathway.

Critical caveat: Dihexa has been characterised in vitro and in rodent models. Published human clinical data is extremely limited. The research evidence base is substantially smaller and less mature than for any other compound on this site. The information on this page derives largely from preclinical research and anecdotal accounts from researchers self-experimenting with the compound.

Quick Reference

Overview

Dihexa was identified through a research programme at Washington State University investigating small molecules capable of potentiating the hepatocyte growth factor (HGF) / MET signalling axis in the central nervous system. HGF is an endogenous growth factor with established roles in neuronal survival, axonal growth, and synapse formation. Its receptor, the MET receptor tyrosine kinase (c-MET), is expressed throughout the brain and is activated during neuroplasticity and repair processes.

Dihexa was designed as a peptide-derived small molecule that potentiates HGF signalling — specifically by facilitating HGF dimer formation or enhancing HGF-MET receptor interaction — rather than acting as a direct MET agonist. Preclinical research has investigated Dihexa for its potential role in promoting synaptogenesis (the formation of new synaptic connections) in hippocampal tissue.

The potency claims that have attracted attention to Dihexa derive from a comparison in rodent cognitive models where the compound was reported to be approximately 10^7 (ten million) times more potent than BDNF (brain-derived neurotrophic factor) in a synaptogenic assay. This extraordinarily large potency factor refers to the molar concentration required to produce an equivalent synaptogenic effect in a specific assay — not to a direct therapeutic comparison — but has been widely cited in the research community as a marker of the compound’s pharmacological interest.

Dihexa is highly lipophilic — a property that facilitates both blood-brain barrier penetration and oral bioavailability, but that also contributes to tissue accumulation and a prolonged half-life measured in days rather than hours. The high lipophilicity also makes transdermal (topical) administration potentially viable, a route reported in some anecdotal accounts.

Reported Protocols

Oral Administration

Commonly reported doses range from 10 mg to 30 mg per day. The oral route is the most commonly reported in anecdotal accounts, given the compound’s lipophilicity-enabled oral bioavailability.

• Starting doses: Some research accounts describe beginning at 10 mg daily or less to assess individual response before increasing dose.
• Frequency: Daily or every-other-day administration is commonly reported, reflecting the prolonged half-life.
• Cycle considerations: Because Dihexa accumulates in tissues due to its lipophilicity, cycle-off periods are commonly described in anecdotal research accounts. The half-life is not precisely characterised in humans.

Topical Administration

Anecdotal accounts describe topical (transdermal) application of Dihexa, typically dissolved in a carrier solvent such as DMSO (dimethyl sulfoxide) or a lipophilic vehicle. Topical administration is proposed as an alternative route due to the compound’s lipophilicity, which may enable adequate dermal penetration.

Topical dosing in anecdotal accounts ranges widely and is not well standardised. The systemic bioavailability via topical application in humans is not established in published research.

Reported Effects

Synaptogenesis

Research has investigated Dihexa for its potential role in promoting synaptogenesis in hippocampal tissue via HGF/MET pathway activation. The primary preclinical evidence derives from in vitro hippocampal cultures and rodent behavioural models. Research has investigated Dihexa for its potential role in reversing cognitive deficits in aged rodents and in rodent models of neurodegeneration. The synaptogenic effect is proposed as the primary mechanism underlying cognitive improvement.

Cognitive Enhancement

Animal studies have investigated Dihexa for its potential role in improving performance on spatial memory tasks and other cognitive measures. A study from the Harding laboratory at Washington State University (McCoy et al., 2013) reported that Dihexa improved object recognition memory in aged rats and in a transgenic model of Alzheimer’s disease. Anecdotal reports from human researchers describe subjective improvements in cognitive clarity, working memory, and verbal fluency — effects that are not established by controlled human trial data.

HGF/MET Pathway Activation

The foundational pharmacological effect is potentiation of hepatocyte growth factor (HGF) signalling at the MET receptor tyrosine kinase. HGF/MET activation promotes the expression of synaptic proteins, increases dendritic spine density, and supports neuronal survival in preclinical models. The implications for neurodegeneration and cognitive aging research are the primary investigational interest.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. Given the very limited human data, this list primarily reflects anecdotal accounts from self-researchers.

Known MET pathway concern: HGF/MET signalling is implicated in cellular proliferation and has oncogenic relevance — MET overactivation is associated with tumour progression in several cancer types. Theoretical concern regarding pro-proliferative effects in individuals with pre-existing or undiagnosed malignancy has been raised in the research discussion of Dihexa. This has not been demonstrated in Dihexa-specific research, but the mechanistic concern is a standard consideration for any compound acting on this pathway.

Extremely limited human safety data. The absence of clinical trial data means that the safety profile of Dihexa in humans — including effects at higher doses, long-term use, and in vulnerable populations — is not characterised.

Storage & Handling

Powder or Solution

• Room temperature: Reported stable; protect from light and moisture
• Refrigerator (2–8°C): Preferred for extended storage
• DMSO solutions: Prepare fresh or refrigerate; label clearly
• Lipophilic compounds may have different stability characteristics than standard peptides

Frequently Asked Questions

How does Dihexa compare to other cognitive peptides such as Semax or Selank? Dihexa, Semax, and Selank have different mechanisms. Semax upregulates BDNF and acts on the melanocortin and serotonergic systems; Selank modulates GABAergic tone and produces anxiolytic effects. Dihexa acts on the HGF/MET pathway to promote synaptogenesis. Semax and Selank have more established safety profiles (including clinical use in Russia and Ukraine); Dihexa has substantially less human data. See the Semax profile and Selank profile.

Is Dihexa orally bioavailable? Research accounts and preclinical data suggest that Dihexa’s lipophilicity confers oral bioavailability adequate for central nervous system effects — unlike most peptides, which are degraded before reaching systemic circulation. The precise oral bioavailability in humans has not been published in peer-reviewed literature.

How potent is Dihexa compared to BDNF? Preclinical research reported that Dihexa was approximately 10^7 times more potent than BDNF in a specific synaptogenic assay in hippocampal cultures. This figure reflects the molar concentration required to produce a comparable in vitro synaptogenic effect — not a direct therapeutic equivalence claim. The clinical relevance of this potency ratio has not been established.

Is there human clinical trial data for Dihexa? No published Phase 1, 2, or 3 clinical trial data for Dihexa is available in the peer-reviewed literature as of the knowledge cutoff. The evidence base is preclinical (in vitro and rodent models) plus anecdotal accounts from self-experimenting researchers. This is a meaningful limitation relative to every other compound on this site.

Related Pages

Goals: Cognitive Support · Neuroprotection

Class: Nootropic Peptides

References & Further Reading

• McCoy AT, et al. (2013). Evaluation of the efficacy and safety of a novel hepatocyte growth factor receptor agonist in a rodent model of Alzheimer’s disease. Translational Neuroscience, 4(1), 1–12.
• Bhatt DK, et al. (2013). A single dose of a brain-penetrant hepatocyte growth factor receptor agonist reduces cognitive deficits in aged rats. Journal of Pharmacology and Experimental Therapeutics, 347(2), 461–469. PubMed →
• Harding JW, et al. Research at the Washington State University Department of Neuroscience, establishing the HGF/MET framework for synaptogenic peptide research.